Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
$11.79
-3.4%
$12.40
$9.76
▼
$28.23
$1.53BN/A878,180 shs418,799 shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$14.53
-1.6%
$18.32
$14.53
▼
$24.68
$1.56B0.452.98 million shs1.86 million shs
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
$21.04
+4.8%
$22.90
$16.77
▼
$39.53
$419.75M3.51252,951 shs169,433 shs
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$9.15
-1.1%
$11.07
$5.32
▼
$14.38
$1.57B1.72.46 million shs2.15 million shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
-2.94%-14.33%+8.44%-33.41%+1,219,999,900.00%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-2.38%-10.05%-13.63%-25.14%-15.79%
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
-4.29%-8.60%-2.76%-45.79%+9.25%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-3.44%-29.66%-7.13%-5.32%+68.49%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
$11.79
-3.4%
$12.40
$9.76
▼
$28.23
$1.53BN/A878,180 shs418,799 shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$14.53
-1.6%
$18.32
$14.53
▼
$24.68
$1.56B0.452.98 million shs1.86 million shs
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
$21.04
+4.8%
$22.90
$16.77
▼
$39.53
$419.75M3.51252,951 shs169,433 shs
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$9.15
-1.1%
$11.07
$5.32
▼
$14.38
$1.57B1.72.46 million shs2.15 million shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
-2.94%-14.33%+8.44%-33.41%+1,219,999,900.00%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-2.38%-10.05%-13.63%-25.14%-15.79%
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
-4.29%-8.60%-2.76%-45.79%+9.25%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-3.44%-29.66%-7.13%-5.32%+68.49%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
2.78
Moderate Buy$43.00259.53% Upside
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
2.00
Hold$23.6762.27% Upside
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
2.80
Moderate Buy$69.17228.58% Upside
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.78
Moderate Buy$22.57148.26% Upside

Current Analyst Ratings Breakdown

Latest TECX, VIR, KLRA, and SRPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/12/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
UpgradeSell (E+) ➝ Sell (D)
11/10/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
UpgradeSell ➝ Hold$14.00 ➝ $18.00
11/10/2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Boost Price TargetOverweight$25.00 ➝ $28.00
11/9/2026
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
Initiated CoverageBuy$44.00
11/9/2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Reiterated RatingBuy$22.00
11/6/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Set Price Target$18.00
11/6/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Boost Price TargetSector Perform$17.00 ➝ $18.00
11/5/2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Boost Price TargetBuy$18.00 ➝ $20.00
11/4/2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
UpgradeStrong Sell ➝ Hold
10/28/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
DowngradeSell (D-) ➝ Sell (E+)
10/21/2026
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
UpgradeSell (D-) ➝ Sell (D)
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
N/AN/AN/AN/A$7.94 per shareN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$2.20B0.71N/AN/A$14.26 per share1.02
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
N/AN/AN/AN/A$11.50 per shareN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$68.56M22.71N/AN/A$5.23 per share1.74
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
-$148.96M-$3,651.83N/AN/AN/AN/A-102.35%-38.58%N/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-$713.41M-$1.37N/A13.500.37-5.86%-0.20%-0.09%N/A
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
-$74.15M-$4.63N/AN/AN/AN/A-37.69%-35.65%N/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$437.99M-$1.26N/AN/AN/AN/A-21.38%-16.97%N/A

Latest TECX, VIR, KLRA, and SRPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$0.0790$0.13+$0.0510-$0.27$352.20 million$381.35 million
11/5/2026Q3 2026
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
-$1.32-$1.08+$0.24-$1.08N/AN/A
11/4/2026Q3 2026
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
-$1.55-$0.74+$0.81-$0.74N/AN/A
11/4/2026Q3 2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$0.7493-$0.57+$0.1793-$0.57$0.98 million($0.19) million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
N/AN/AN/AN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
N/AN/AN/AN/AN/A
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
N/AN/AN/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
N/A
21.84
21.84
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.46
3.46
2.13
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
N/A
19.71
19.71
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/A
6.30
6.30

Institutional Ownership

CompanyInstitutional Ownership
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
N/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
86.68%
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
62.63%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
65.32%
CompanyEmployeesShares OutstandingFree FloatOptionable
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
145129.85 millionN/AOptionable
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
835107.24 million99.84 millionOptionable
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
6019.95 million12.01 millionOptionable
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
367171.27 million166.30 millionOptionable

Recent News About These Companies

Why is Vir Biotechnology stock falling Friday?
Vir Biotechnology stock tumbles on $150M share offering
HC Wainwright Has Optimistic Opinion of VIR FY2026 Earnings
Vir Biotechnology Announces Proposed Public Offering
TD Cowen Reaffirms Their Buy Rating on Vir Biotechnology (VIR)
Is Vir Biotechnology (VIR) Overvalued After Its 127% Run?
What is HC Wainwright's Estimate for VIR FY2026 Earnings?
Vir Biotechnology (NASDAQ:VIR) Earns "Buy" Rating from HC Wainwright

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Kailera Therapeutics stock logo

Kailera Therapeutics NASDAQ:KLRA

$11.79 -0.41 (-3.36%)
As of 04:00 PM Eastern

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. With our obesity-first focus, we have built a diversified pipeline of product candidates specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate that we believe offers the potential for the greatest weight loss. We are rapidly progressing four clinical-stage product candidates, leveraging multiple glucagon-like peptide-1, or GLP-1, based mechanisms of action and routes of administration. Our lead product candidate, ribupatide (also known as KAI-9531), is currently being evaluated in global Phase 3 trials as a once-weekly injectable GLP-1/glucose-dependent insulinotropic polypeptide, or GIP, receptor dual agonist peptide that we believe offers the potential for the greatest weight loss compared to all obesity management medications currently marketed or in development with a tolerability profile that is class-like or better. We are expanding our ribupatide franchise by developing a once-daily oral tablet formulation, oral ribupatide, based on the same peptide as injectable ribupatide, to provide a convenient oral option with the potential for highly differentiated tolerability with compelling weight loss among oral treatments. Additionally, we are advancing a second oral product candidate, KAI-7535, a once-daily small molecule GLP-1 receptor agonist with the potential to improve on the clinical profile of existing oral treatments. Finally, we are developing KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist, that leverages an incremental mechanism to potentially deliver compelling weight loss, improved liver fat reduction and a differentiated tolerability profile. KAI-4729 is based on a different peptide than injectable ribupatide and oral ribupatide. Obesity is a chronic, complex disease characterized by the accumulation of excessive body fat, resulting in significant negative impacts on health and quality of life. The most severely impacted patient population, people with a body mass index, or BMI, of 35 kg/m2 or greater, which we refer to as a BMI of 35+, represents the fastest growing and largest segment of this population, with half of U.S. adults with obesity expected to have a BMI of 35+ by 2030. While the approvals of GLP-1-based obesity management medications have changed the landscape of obesity management, there remains a critical need for medications offering greater weight loss, especially for those living with a higher BMI. For example, in the SURMOUNT-1 Phase 3 clinical trial, the majority of patients who had a baseline BMI of 35+ and were treated with tirzepatide, the most prescribed weight loss medicine today, were still living with obesity at the end of treatment. Both physicians and patients have identified expected weight loss as a primary treatment goal, with the magnitude of weight reduction serving as a crucial driver in therapy selection. We believe that injectable treatments will remain foundational for patients needing significant weight reduction. Meanwhile, for patients with a lower BMI, lower incidences of gastrointestinal side effects may be needed to achieve optimal weight loss and treatment persistence, and we believe oral treatments can unlock adoption for those with more modest weight loss needs, while also supporting the chronic treatment journey of those living with higher BMIs. We were originally incorporated under the laws of the State of Delaware on May 8, 2024 under the name Hercules CM Newco, Inc. We changed our name to Kailera Therapeutics, Inc. on August 22, 2024. Our principal executive offices are located in Waltham, Massachusetts.

Sarepta Therapeutics stock logo

Sarepta Therapeutics NASDAQ:SRPT

$14.53 -0.24 (-1.62%)
Closing price 04:00 PM Eastern
Extended Trading
$14.71 +0.18 (+1.27%)
As of 05:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Tectonic Therapeutic stock logo

Tectonic Therapeutic NASDAQ:TECX

$21.04 +0.96 (+4.78%)
Closing price 04:00 PM Eastern
Extended Trading
$21.44 +0.40 (+1.90%)
As of 05:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

Vir Biotechnology stock logo

Vir Biotechnology NASDAQ:VIR

$9.15 -0.10 (-1.08%)
Closing price 04:00 PM Eastern
Extended Trading
$9.25 +0.10 (+1.08%)
As of 05:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.